Plain-English translation of NCT05577988 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a heart attack, most patients take two blood-thinning medications to prevent future clots. But people at high risk of bleeding face a difficult choice: continue both medications (which increases bleeding risk) or switch to just one. This trial compares two strategies after one month: switching to a stronger single blood thinner like ticagrelor or prasugrel versus switching to a gentler blood thinner (clopidogrel or aspirin) that's chosen based on your genes. The goal is to find which approach best protects you from dangerous bleeding while still preventing another heart attack.
Current treatment guidelines don't clearly guide doctors on the safest approach for patients at high bleeding risk. This medication and strategy may reduce bleeding complications while still keeping patients safe from future heart attacks.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital or clinic 1 to 3 months after your heart attack and have a quick genetic test (a mouth swab that gives results within an hour). You'll then be randomly assigned to one of two groups: one group will switch to a stronger single blood thinner, while the other will switch to a gentler blood thinner chosen based on your genetic results. After that, you'll take your assigned medication and have follow-up visits where doctors monitor you for bleeding and other heart events. The study follows you over time to see which approach works best for people with high bleeding risk.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
France